A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...

Pioneering clinical trial testing how personalised mRNA vaccines can enable the immune system to target recurring pancreatic cancer.

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...

AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM” or the 'Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3 ...

Pancreatic cancer is one of the hardest cancers to treat, which makes early detection so crucial, now AI is lending a hand to speed up the process.

A newly discovered gene switch may help turn chemotherapy-resistant pancreatic cancer into a treatable disease.

Cancer cachexia impacts almost 90% of people living with pancreatic cancer. Learn more about this condition in this Q&A with Nicolas Clifford, PanCAN’s manager of research and education communication.

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

Researchers have identified a molecular "switch" that determines whether pancreatic cancer responds to or resists treatment, ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...